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the presence and severity of atherosclerotic coronary artery disease
(CAD) [4]. In this study, we sought to investigate whether EAT could
also contribute to the inﬂammatory burden of AS. To this aim, we ana-
lyzed echocardiographic EAT thickness and EAT secretory proﬁle ob-
tained from patients with calciﬁc AS.
We enrolled 95 patients with severe, isolated, calciﬁc AS, referred to
cardiac surgery for aortic valve (AV) replacement. Exclusion criteria
were: 1) pathologic conditions already known to be associated with in-
creased echocardiographic EAT thickness and/or altered inﬂammatory
EAT status (CAD, metabolic syndrome, atrial ﬁbrillation) [3,5]; and 2)It is widely recognized that biological processes leading to calciﬁc
aortic stenosis (AS) include chronic inﬂammation, lipoprotein deposi-
tion and activation of speciﬁc osteogenic and apoptotic signaling path-
ways [1]. These phenomena resemble those observed in the early
stages of coronary artery disease (CAD). Further, AS and CAD share com-
mon risk factors, early pathogenesis, and clinical coexistencewith a high
percentage (40% to 75%) of patients with severe AS and concomitant
CAD [2]. Thus, it is reasonable to hypothesize that the pathogenesis
and progression of AS and CAD might be induced by similar stimuli,
largely represented by the inﬂammatory activity intrinsic to the athero-
genic process.
Epicardial adipose tissue (EAT) represents a visceral fat depot which
plays several protective functions for the heart in physiologic condi-
tions [3]. However, it is known that EAT may also play an unfavorable
activity for the heart. In fact, it is a source of several pro-inﬂammatory
and pro-atherogenic cytokines, which can biologically inﬂuence the
myocardium and epicardial coronary arteries through paracrine or
vasocrine actions [3]. It has been reported that EAT thickness representsediche Traslazionali, Università
apoli, Italy.
reliability and freedom frombi-
n.
.a speciﬁc marker of visceral adiposity which is strongly associated with
chronic inﬂammatory diseases which could affect EAT thickness and/
or systemic and local inﬂammatory proﬁles. The study protocol con-
forms to the ethical guidelines of the 1975 Declaration of Helsinki as
reﬂected in a priori approval by our institution's human research com-
mittee. All patients provided written informed consent.
Wemeasured EAT thickness by echocardiography in AS patients and
in a control group of 44 healthy subjects matched for age, gender and
body mass index (BMI). Intra and inter-observer reproducibility for
echocardiographic EAT thickness assessment was excellent (0.962 and
0.951, respectively).
In patients referred to aortic valve replacement, plasma and EAT
were collected and analyzed by human cytokine 27multiplex immuno-
assay for the assessment of systemic and local inﬂammatory status.
Table 1 illustrates demographic and clinical characteristics of the study
population. EAT thickness was markedly increased in patients with AS
with respect to controls (9.85 ± 2.78 vs 4.91 ± 1.27 mm; p b 0.0001).
Demographic and clinical variables were also evaluated after study pop-
ulation stratiﬁcation above and below EAT thickness median value
(10 mm). There were no differences between the two groups for age,
BMI, glomerular ﬁltration rate, and atherosclerotic risk factors. Interest-
ingly, as regard to cardiovascular therapy, only statin use was signiﬁ-
cantly higher (p b 0.04) in patients below the EAT thickness median
value. No differences were found between the two groups in plasma in-
ﬂammatory mediator levels, except for PDGF and VEGF. Contrarily, in
EAT secretome, 22 of 27 measured inﬂammatory mediator levels were
signiﬁcantly higher in patients above the EAT thickness median value
(Table 2). Further, EAT levels of several inﬂammatory cytokines, such
as IL-6, IL-8, IL-1β, and TNF-α showed a highly signiﬁcant increase
Table 1
Demographic and clinical characteristics of the study population.
Age, years 72.52 ± 11.22
Gender Female, % (n) 60.0% (57)
BMI 27.66 ± 4.61
Dyslipidemia, % (n) 42.1% (40)
Diabetes, % (n) 29.5% (28)
Hypertension, % (n) 66.3% (63)
Smokers, % (n) 26.3% (25)
GFR b 60 ml/min 8.4% (8)
Medications
Aspirin, % (n) 40.0% (38)
Statin, % (n) 37.9% (36)
ACE-I/ARBs, % (n) 53.7% (51)
BBs, % (n) 51.6% (49)
Echocardiographic characteristics
LVEF, % 64.35 ± 12.33
E/A 3.16 ± 15.75
E Dec, msec 248.50 ± 87.77
E/e′ 15.43 ± 5.96
AV area, cm2 0.8 ± 0.2
Mean gradient, mm Hg 44.27 ± 19.66
Mass, gr 180.50 ± 45.02
Mass/BSA, gr/m2 99.36 ± 27.66
RWT 0.44 ± 0.10
EAT thickness, mm 9.85 ± 2.78
BMI, body mass index; GFR, glomerular ﬁltration rate; ACE-I, Angiotensin
Converting Enzyme inhibitors; ARB, Angiotensin Receptor Blockers; BBs,
Beta-blockers; LVEF, Left Ventricular Ejection Fraction; AV, aortic valve;
BSA, Body Surface Area; RWT, Relative Wall Thickness; EAT, epicardial ad-
ipose tissue.
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relationship between EAT echocardiographic thickness and its inﬂam-
matory proﬁle. Interestingly, we found a close direct correlation be-
tween EAT thickness and levels of secreted inﬂammatory mediators.
In particular, EAT thickness signiﬁcantly correlated with levels of IL-Table 2
Plasma and EAT secretory proﬁle of AS patients stratiﬁed according to EAT thickness median v
PLASMA EAT
Pts below EAT thickness median
value pg/ml
Pts above EAT thickness median
value pg/ml
p
valu
Mean ± SD Mean ± SD
PDGF 2212.1 ± 995.7 1107.0 ± 625.1 .010
IL-1β 4.8 ± 2.2 4.8 ± 1.5 .963
IL-1ra 525.1 ± 304.9 447.4 ± 242.3 .541
IL-2 30.2 ± 41.8 24.2 ± 38.1 .748
IL-4 4.6 ± 1.7 3.5 ± 1.3 .129
IL-5 3.5 ± 1.4 4.2 ± 2.5 .340
IL-6 43.0 ± 34.8 27.6 ± 16.3 .255
IL-7 17.6 ± 8.1 18.0 ± 17.1 .938
IL-8 61.6 ± 32.6 44.3 ± 14.1 .172
IL-9 26.4 ± 13.4 28.4 ± 22.9 .792
IL-10 50.3 ± 59.4 35.0 ± 29.4 .503
IL-12 56.3 ± 47.4 41.7 ± 51.6 .504
IL-13 15.2 ± 7.1 11.4 ± 7.9 .246
IL-15 74.8 ± 27.6 132.3 ± 56.3 .093
IL-17 110.5 ± 58.4 128.1 ± 128.6 .655
Eotaxin 119.6 ± 44.9 124.0 ± 97.7 .888
FGF basic 95.6 ± 33.1 135.6 ± 103.1 .176
G-CSF 111.3 ± 46.3 131.8 ± 62.6 .382
GM-CSF 119.7 ± 83.5 124.6 ± 130.6 .913
IFN-γ 159.2 ± 80.4 147.6 ± 38.4 .707
IP-10 1635.3 ± 1125.0 1116.5 ± 603.5 .241
MCP-1 152.4 ± 55.9 146.0 ± 117.3 .859
MIP-1α 8.4 ± 6.5 9.8 ± 7.3 .646
MIP-1β 226.9 ± 238.4 148.4 ± 58.0 .375
RANTES 26,332 ± 26,881 12,707.6 ± 10,742. 5 .187
TNF-α 51.9 ± 23.4 80.8 ± 64.4 .129
VEGF 187.6 ± 102.0 64.6 ± 44.4 .004
EAT, epicardial adipose tissue; AS, aortic stenosis.1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-17, basic
FGF, eotaxin, G-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF and
TNF-α.
The relationship between EAT thickness and the presence and sever-
ity of atherosclerotic CAD has been well established [4]. Of note, our
study provides the ﬁrst evidence that EAT thickness is also increased
in patients with isolated AS. This observation further supports previous
evidence indicating that CAD and AS share common pathogenetic
mechanisms. In this regard, histologic studies have demonstrated that,
in the early AS disease, the biological processes show similar character-
istics to those observed in the coronary atherosclerotic plaque [6].
The ‘atherogenicity’ of EAT is addressed to secretion of inﬂammatory
cytokines, such as TNF-α, MCP-1, IL-6, IL-1β, plasminogen activator
inhibitor-1 and resistin [7]. Interestingly, in CAD patients, local levels
of these inﬂammatory mediators do not correlate with plasma concen-
trations of circulating cytokines and are independent of several clinical
variables, such as obesity, and diabetes [7]. The present study evaluated
the secretory characteristics of EAT secretome of patients with AS. We
found that several inﬂammatory and pro-atherogenic mediators were
signiﬁcantly increased in EAT. In particular, IL-6 showed an enormous
increase in EAT with respect to plasma. The involvement of IL-6 in AS
has been recently described by El Husseini et al. [8]. These authors dem-
onstrated that high expression of IL-6 promotes themineralization pro-
cess of AV leaﬂets, which is partially reversed by IL-6 inhibition. Further,
it has been described that pro-inﬂammatory stimulation promotes the
transition of AV interstitial cells toward inﬂammatory cells resulting in
a signiﬁcantly increased production of IL-6, IL-8 and MCP-1 [9]. As re-
gard to IL-1β, we found a twelve fold increase of this cytokine in EAT
secretome compared to systemic values. Histologic studies of stenotic
AV leaﬂets have demonstrated increased levels of this potent pro-
inﬂammatory cytokine which promotes matrix metalloproteinase ex-
pression and cell proliferation in calciﬁc AV and has been implicated
in the pathogenesis of several inﬂammatory diseases [9]. TNF-α, that
showed 2.3 fold increase in EAT vs plasma in our study, has also beenalue.
e
Pts below EAT thickness median
value pg/ml
Pts above EAT thickness median
value pg/ml
p value
Mean ± SD Mean ± SD
34.1 ± 1.8 67.0 ± 32.8 .056
47.8 ± 10.5 84.4 ± 6.3 .000
685.2 ± 137.6 1436.1 ± 163.6 .000
17.9 ± 1.6 81.4 ± 6.9 .000
2.5 ± 0.9 6.8 ± 1.0 .000
1.5 ± 0.5 3.3 ± 1.1 .010
52,114 ± 28,322. 112,394.1 ± 18,003.4 .004
2.7 ± 0.6 5.3 ± 0.8 .000
7222.9 ± 3785.8 134,151.5 ± 14,886.3 .000
6.3 ± 1.8 18.0 ± 1.8 .000
33.4 ± 3.0 229.8 ± 99.6 .002
32.6 ± 8.2 84.1 ± 48.7 .048
13.2 ± 3.0 12.7 ± 2.7 .792
322.6 ± 54.7 388.4 ± 50.5 .083
41.7 ± 15.3 240.7 ± 34.6 .000
26.0 ± 7.2 177.3 ± 15.6 .000
205.7 ± 39.8 389.0 ± 104.7 .006
3548.6 ± 615.5 85,329.2 ± 81,013.9 .054
612.5 ± 21.5 620.9 ± 103.6 .864
134.5 ± 18.4 371.6 ± 42.7 .000
179.9 ± 140.5 3809.0 ± 2601.8 .014
3709.8 ± 190.5 18,155.8 ± 2274 .000
30.7 ± 4.3 638.6 ± 122.3 .000
368.3 ± 93.7 1646.2 ± 174.7 .000
233.4 ± 150.7 301.3 ± 98.2 .423
63.9 ± 9.6 207.8 ± 17.6 .000
465.1 ± 198.3 1143.4 ± 805.6 .105
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human AV interstitial cells obtained from patients with calciﬁc AS
[10]. Overall these ﬁndings, indicating a potent pro-inﬂammatory acti-
vation of EAT in patientswith isolated AS, togetherwith the strong asso-
ciation observed between EAT thickness and AS, support the hypothesis
of an involvement of cardiac visceral fat in inﬂammatory and athero-
genic phenomena occurring in the AV and promoting its degeneration
and calciﬁcation.
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